FAAH-mediated diseases including comprising an active agent and a second oxazole inhibitors of FAAH or imidazole is selected, the activation of the second and FAAH inhibitor, the invention is directed to compositions useful in the treatment of disorders or diseases . Osteoarthritis, rheumatoid arthritis, diabetic neuropathy, post-herpetic neuralgia, skeletal muscle pain, and fibromyalgia, as well as acute pain, migraine, sleep disorders, Alzheimers disease and the composition, wider, including Parkinsons disease It would be useful range of diseases, in the treatment of disorders or diseases. In one aspect, is directed to compositions useful in the treatment of nociceptive pain and neuropathic pain, the invention disclosed herein, including etoricoxib composition other.本発明は、選択されたイミダゾールまたはオキサゾールFAAH阻害剤および第二の活性剤を含む、FAAH阻害剤および第二の活性化を含むFAAH媒介病、障害または疾患の治療で有用な組成物に向けられる。該組成物は、骨関節炎、慢性関節リウマチ、糖尿病性神経障害、ヘルペス後神経痛、骨格筋疼痛、および線維筋痛症、ならびに急性疼痛、片頭痛、睡眠障害、アルツハイマー病およびパーキンソン病を含めた広い範囲の病気、障害または疾患の治療で有用であろう。もう1つの局面において、本明細書中に開示された発明は、神経因性疼痛および侵害受容性疼痛の治療で有用な組成物に向けられ、該組成物はエトリコキシブを含む。
